Home News HCV Treatment Enters Transformative Era HCV Treatment Enters Transformative Era June 15, 2011 June 15, 2011 (Vol. 31, No. 12) Hepatitis C Virus Protease Inhibitor Agents Herals Major Advances in Field NewsAntiviral agentsCellular, Molecular and Developmental BiologyDiagnosisDNA typingDNA virusesDrugsForensic geneticsGeneticsHepatitis virusMedicine, Diagnosis, and TherapeuticsMicrobiologyMicroorganismsMolecular biologyPharmacologyPolymerase chain reactionPrognosisRNA biologySustained virologic responseTreatment outcomeViral RNAVirus Also of Interest HIV-Free Hopes Raised by Reservoir-Targeting VLPs Rising from the Ashes: FDA Grants EUA to Invivyd COVID-19 Antibody Novo Nordisk to Acquire Cardior for Up to $1.1B, Boosting Cardiovascular Pipeline StockWatch: CDMOs Tumble as Congress Takes Aim at Chinese Biotechs 10x Ships First Single Cell GEM-X Assays to Customers StockWatch: Blockbuster Sales Projected for Madrigal MASH Drug Related Media Genetics in DC: A Report from ASHG BIO CEO Rachel King Outlines Industry's Challenges on "Close to the Edge" Carl Icahn States His Case for Change at Illumina on "Close to the Edge" Celebrating DNA: Matthew Cobb's Reflections on the Double Helix Emerging Markets Collaborate to Succeed in Post-Pandemic World Food For Thought: Final Report from the AGBT Ag Meeting Related Content HIV-Free Hopes Raised by Reservoir-Targeting VLPs Rising from the Ashes: FDA Grants EUA to Invivyd COVID-19 Antibody Novo Nordisk to Acquire Cardior for Up to $1.1B, Boosting Cardiovascular Pipeline StockWatch: CDMOs Tumble as Congress Takes Aim at Chinese Biotechs